Advertisement

Advertisement

Multiple Myeloma

The Implications of the Results From CARTITUDE-1 for Future Research and Care in Multiple Myeloma

The results from the CARTITUDE-1 study showed the remarkable efficacy of ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, when used in patients with relapsed or refractory multiple myeloma after four or more prior lines of...

Multiple Myeloma

Do the Results From CARTITUDE-1 Represent a Cure for Patients With Multiple Myeloma? We Need Longer Follow-Up to Know for Sure

The results of the CARTITUDE-1 clinical trial demonstrate outstanding and unprecedented long-term efficacy with ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory multiple myeloma.1 (See the July 2025 issue of The ...

Multiple Myeloma
Lymphoma

Rare Secondary Cancer After CAR T-Cell Therapy Successfully Treated, Case Report Shows

In a case presentation published in The New England Journal of Medicine, targeted treatment was successful for chimeric antigen receptor (CAR)-positive peripheral T-cell lymphoma developed after CAR T-cell therapy for multiple myeloma.  Using advanced genomic, phenotypic, and functional profiling...

Multiple Myeloma

Smoldering Multiple Myeloma: How the Guidance Is Changing

Clinical trials have sought to determine the benefit of treating the precursors of multiple myeloma, but as the phenotypes and genomics of this entity are becoming better delineated, the wisdom of early intervention has remained confusing for clinicians. At the 2025 Debates and Didactics in...

multiple myeloma

Case 3: Optimal Sequencing of T-Cell–Redirected Therapies

This is Part 3 of Navigating the T-Cell Therapy Landscape in Multiple Myeloma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Kenneth Anderson, Ajai Chari, and Noopur Raje discuss the treatment of a patient with high-risk multiple myeloma that is progressing following maintenance therapy. The patient is a 65-year-old man with back pain, anemia, and lytic bone disease with 70% bone marrow plasma cells (deletion 17p and 1q amplification) His IgA kappa is 6.5 g/dL, and his kappa:lambda ratio is 800. He is treated with isatuximab, carfilzomib, lenalidomide, and dexamethasone, achieving a measurable residual disease (MRD)-negative complete response after eight cycles. He undergoes stem cell collection, but defers autologous stem cell transplant and receives carfilzomib plus lenalidomide maintenance for 2 years. Four years later, he has increasing MRD while in complete response.   In the conversation that follows, the faculty discuss how increasing MRD informs treatment decisions, the clinical data supporting the use of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel, and considerations when sequencing CAR T-cell therapies and bispecific T-cell engagers.

multiple myeloma

Case 2: Role of T-Cell–Redirected Therapies in Elderly Patients With Relapsed/Refractory Multiple Myeloma

This is Part 2 of Navigating the T-Cell Therapy Landscape in Multiple Myeloma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Kenneth Anderson, Ajai Chari, and Noopur Raje discuss the treatment of a patient with relapsed multiple myeloma. The patient is an 80-year-old woman with hematocrit of 30, compression fractures in the thoracic and lumbar spine, and normal calcium and renal function. A bone marrow biopsy shows 80% plasma cells with hyperdiploidy; her IgA is 1,600 mg/dL, and the kappa:lambda ratio is 200. She receives RVD-lite, achieving a very good partial response. However, 2 years later, her IgA and kappa:lambda ratio are found to be increasing.   In the conversation that follows, the faculty discuss the optimal salvage therapy for this patient, the role that chimeric antigen receptor T-cell therapies play at first relapse, and the impact of frailty status on choice of therapy.

multiple myeloma

Case 1: Role of ASCT in the Era of Quadruplet Induction and T-Cell–Redirected Therapies

This is Part 1 of Navigating the T-Cell Therapy Landscape in Multiple Myeloma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Kenneth Anderson, Ajai Chari, and Noopur Raje discuss the treatment of a patient with newly diagnosed multiple myeloma. The patient is a 65-year-old man who presents with back pain. He is found to have IgG kappa 4.5 g/dL, kappa:lambda ratio of 250, and 70% bone marrow plasma cells with 1q amplification and t(4:14). His calcium and renal function are normal, but he is found to have diffuse bone disease.   In the conversation that follows, the faculty discuss the many quadruplet induction therapies that may be an option for this patient, the role that measurable residual disease plays in determining the best course of therapy, whether autologous stem cell transplant is still necessary, and how they are incorporating CAR T-cell therapy and bispecific T-cell engagers into the initial management of newly diagnosed multiple myeloma.

Multiple Myeloma

Novel Single-Cell Sequencing Blood Test for Multiple Myeloma

Researchers at Dana-Farber Cancer Institute have developed a blood test that may alter the diagnosis and monitoring of multiple myeloma and its precursor conditions. The new method, known as SWIFT-seq, uses single-cell sequencing to profile circulating tumor cells (CTCs) in the blood, offering a...

Multiple Myeloma

Evidence of Potential Cure With Single CAR T-Cell Infusion for Some Patients With Multiple Myeloma

In long-term results from the CARTITUDE-1 trial, investigators had found that the autologous cellular immunotherapy ciltacabtagene autoleucel was potentially curative for one-third of patients with heavily pretreated relapsed or refractory multiple myeloma.1 These patients remained progression-free ...

Multiple Myeloma

DREAMM-7 Analysis Compares Survival Outcomes Between Triplet Regimens for Relapsed or Refractory Multiple Myeloma

In an analysis from the phase III DREAMM-7 trial reported in The Lancet Oncology, Hungria et al compared survival outcomes with belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma...

Multiple Myeloma

Teclistamab for High-Risk, Heavily Pretreated Multiple Myeloma: Real-World Data

Teclistamab-cqyv is the first bispecific T-cell engager antibody that targets both B-cell maturation antigen (BCMA) proteins on myeloma cells and CD3 proteins on T cells. It was approved by the U.S. Food and Drug Administration in 2022 for treatment of patients with relapsed or refractory multiple...

Multiple Myeloma

FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma

On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to linvoseltamab-gcpt (Lynozyfic), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of...

Multiple Myeloma

Novel Tri-Specific Antibody Shows Efficacy and Safety in Refractory Myeloma

According to the initial findings of an ongoing first-in-human phase I trial, reported at the European Hematology Association (EHA) 2025 Congress, promising results have been shown for a novel off-the-shelf tri-specific antibody in the treatment of patients with multiple myeloma highly refractory...

Multiple Myeloma

MRD-Guided Treatment in Newly Diagnosed Multiple Myeloma

In a French-Belgian phase III trial (MIDAS) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Perrot et al examined the outcomes of treatments guided by measurable residual disease (MRD) status in patients with newly diagnosed multiple myeloma.  Study Details In...

Multiple Myeloma

Ciltacabtagene Autoleucel Delivers Lasting Remissions in Relapsed or Refractory Multiple Myeloma

New long-term follow-up data from the phase Ib/II CARTITUDE-1 study demonstrated that one-third of patients in the study with relapsed or refractory multiple myeloma treated with the chimeric antigen receptor T-cell therapy ciltacabtagene autoleucel achieved progression-free survival of 5 years or...

Multiple Myeloma

Potential New Standard of Care Emerges in Multiple Myeloma

A new four-drug combination appears to be effective and safe in patients with newly diagnosed multiple myeloma, according to data from the ADVANCE clinical trial conducted by investigators at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine. Presented ...

Multiple Myeloma

Genomic Score May Predict Progression From Precursor Condition to Active Multiple Myeloma

Investigators have developed a genomic score, called multiple myeloma-like (MM-like), for predicting progression from multiple myeloma precursor conditions to active cancer, study results published in Nature Genetics showed. The researchers created a map of the genome of multiple myeloma and its...

Multiple Myeloma

Physical Function Acts as Predictor of Survival for Daratumumab-Based Therapy in Multiple Myeloma

Patients with multiple myeloma who had lower physical function scores at the time of treatment initiation demonstrated a greater benefit to daratumumab treatment than those with higher physical function scores, according to the results of a study published in the European Journal of Haematology....

Multiple Myeloma

Strategy for Managing Immunotherapy-Induced Parkinsonism in Patients With Multiple Myeloma

The JAK (Janus kinase) inhibitor ruxolitinib may prove to be an effective treatment of parkinsonism arising from immunotherapy for patients with multiple myeloma, according to the results of two case reports by Baldeep Wirk, MD, and Jin Lim, MD, PhD, both of Virginia Commonwealth University,...

Bladder Cancer
Thyroid Cancer
Gastroesophageal Cancer
Neuroendocrine Tumors
Colorectal Cancer
Lung Cancer
Lymphoma
Multiple Myeloma

NCCN Clinical Practice Guidelines in Oncology: 2025 Updates

The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are available for more than 60 tumor types, subtypes, and related topics. During the NCCN’s 30th Annual...

Multiple Myeloma

How Could So Many Physicians Have Failed Me?

The first sign that something was terribly wrong was in 2015, when I began to feel so fatigued that it was difficult to get out of bed even after 8 to 10 hours of sleep. I’ve been full of energy my whole life and couldn’t understand why I was so tired all the time. Then I began to experience...

Multiple Myeloma
Symptom Management

Use of Ruxolitinib to Resolve Ciltacabtagene Autoleucel–Induced Parkinsonism in Patients With Multiple Myeloma

Ruxolitinib may prove to be an effective treatment of parkinsonism arising from ciltacabtagene autoleucel treatment for patients with multiple myeloma, according to the results of a case report published in the Journal of Hematology. The report featured two cases of patients with multiple myeloma...

Multiple Myeloma

Addition of Daratumumab to Treatment Regimen in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

As reported in The Lancet Oncology by Mateos et al, the final results of the phase III ALCYONE trial showed persistent benefit with the addition of daratumumab to bortezomib, melphalan, and prednisone (D-VMP) in transplant-ineligible patients with newly diagnosed multiple myeloma. The primary...

Multiple Myeloma

ADAR1 Gene and Response to Lenalidomide in Patients With Multiple Myeloma

Investigators have identified a key component inhibiting responses to lenalidomide in patients with multiple myeloma, according to the results of a study recently published in Blood. They identified adenosine deaminase acting on RNA1 (ADAR1) as a novel driver of acquired resistance to lenalidomide...

Hematologic Malignancies
Multiple Myeloma

MRD-Based Endpoint to Support Accelerated Approval of Treatment for Multiple Myeloma

In a pooled analysis reported in the Journal of Clinical Oncology, Shi et al found that a clinical trial endpoint of complete response with minimal residual disease (also known as measurable residual disease) at the 10-5 threshold (MRD-CR) at 9 or 12 months could be used to support accelerated...

Hematologic Malignancies
Multiple Myeloma

Idecabtagene Vicleucel vs Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma

In a retrospective study reported in the Journal of Clinical Oncology, Hansen et al found that standard-of-care ciltacabtagene autoleucel was associated with better efficacy outcomes and increased risk of some toxicities vs standard-of-care idecabtagene vicleucel in patients with relapsed or...

Hematologic Malignancies
Multiple Myeloma

Effect of High-Risk Cytogenetic Abnormalities in Multiple Myeloma

In a retrospective study reported in the Journal of Clinical Oncology, Kaiser et al found that the presence of two or more high-risk cytogenetic abnormalities was associated with poorer outcomes in patients with newly diagnosed multiple myeloma (MM) and relapsed or refractory MM. Study Details The...

Multiple Myeloma
Genomics/Genetics
Issues in Oncology

Genetic Testing May Identify High-Risk Cytogenetic Abnormalities in Patients With Multiple Myeloma

Offering genetic testing to patients with multiple myeloma may help physicians to determine which patients have the most aggressive types of the disease and how to target their malignancy more effectively, according to a recent study published by Kaiser et al in the Journal of Clinical Oncology....

Multiple Myeloma
Myelodysplastic Syndromes
Leukemia

In Case You Missed It: Additional Studies of Interest From ASH 2024

A record-breaking number of abstracts were submitted for the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, and nearly 8,000 were accepted. The ASCO Post strives to provide in-depth coverage of those with the greatest impact. Here, we offer snapshots of others of...

Multiple Myeloma

AQUILA Trial: Daratumumab Proves Beneficial in Smoldering Multiple Myeloma

Patients with smoldering multiple myeloma derived a significant progression-free survival benefit, along with other positive outcomes, from 3 years of subcutaneous use of the monoclonal antibody daratumumab as compared with active monitoring in the phase III AQUILA study.1 These findings were...

Multiple Myeloma

Talquetamab Plus Teclistamab in Relapsed or Refractory Multiple Myeloma

In a phase Ib-II study (RedirecTT-1) reported in The New England Journal of Medicine, Cohen et al found that the combination of the bispecific antibodies talquetamab (anti–G protein-coupled receptor family C group 5 member D) and teclistamab (anti–B-cell maturation antigen) was associated with a...

Multiple Myeloma

High-Fiber Diet May Slow Disease Progression to Multiple Myeloma

Recent data suggest that a plant-based diet rich in fiber may help to improve the outlook for people with precursor conditions that can lead to multiple myeloma. The research, which involved a 12-week controlled diet with additional health coaching for 20 patients as well as experiments in mice, is ...

Multiple Myeloma

Study Finds Daratumumab Monotherapy Prevented or Delayed Progression From Smoldering to Active Multiple Myeloma

An analysis of the results from the ongoing randomized phase III AQUILA study found that daratumumab monotherapy was well tolerated and demonstrated a clinically meaningful and significant benefit in preventing or delaying progression to active multiple myeloma compared with active monitoring in...

Multiple Myeloma

Will CAR T-Cell Therapy Be the Magic Bullet for My Multiple Myeloma?

Intense pain on the right side of my lower rib cage, in 2020, sent me first to my chiropractor for relief and then to my primary care provider for tests. Because of the location of the pain, the chiropractor thought I might be having a gallbladder attack, but the results from a urine test showed a ...

Pancreatic Cancer
Colorectal Cancer
Multiple Myeloma
Bladder Cancer
Solid Tumors

The Future of Cancer Care, Part 2

The soaring number of cancer survivors since the National Cancer Act of 1971 was enacted into law provides a snapshot of the profound progress made against cancer over the past half-century: 3 million survivors in the 1970s,1 compared to more than 18 million today, and that number is expected to...

Multiple Myeloma

IMF Welcomes Newly Elected Board of Directors Members

The International Myeloma Foundation (IMF) welcomes four of its newest members to the IMF Board of Directors: Director of Strategic Growth at Raanes & Oliver Capital Advisors, Kent Oliver; Managing Partner of Global Commercialization Strategy and Solutions at ZS Associates, Maria Whitman;...

Multiple Myeloma

In Treatment of Transplant-Ineligible Myeloma, Addition of Isatuximab Improves Outcomes

In the phase III IMROZ trial, the addition of the anti-CD38 monoclonal antibody isatuximab-irfc to bortezomib, lenalidomide, and dexamethasone (VRd) was more effective than VRd alone as initial therapy in patients ≤ 80 years with newly diagnosed multiple myeloma ineligible for transplant,...

Multiple Myeloma

Daratumumab Induction Regimen in Transplant-Ineligible Patients Newly Diagnosed with Multiple Myeloma

In the phase III CEPHEUS trial,1 the achievement of undetectable measurable residual disease (or MRD negativity)—the primary endpoint—was met by 61% of patients with transplant-ineligible or deferred newly diagnosed multiple myeloma treated with the monoclonal antibody daratumumab plus bortezomib, ...

Multiple Myeloma

Effect of Myeloma Therapy in a Patient With Monoclonal Gammopathy of Thrombotic Significance

In a letter to the editor in The New England Journal of Medicine, Salmasi et al described identification of monoclonal gammopathy of thrombotic significance (MGTS) in a patient with coronary artery disease and its successful treatment with daratumumab, bortezomib, and dexamethasone (DVd).  As...

Multiple Myeloma

Evolving Role of MRD Status in Multiple Myeloma

The use of measurable (or minimal) residual disease (MRD) status to guide treatment in multiple myeloma has become a topic of intense interest. Phase III studies presented at the Plenary Session of the 2024 International Myeloma Society Annual Meeting moved MRD status ever closer to validation in...

Multiple Myeloma

Isatuximab Plus VRd Approved by FDA for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

On September 20, the U.S. Food and Drug Administration (FDA) approved the monoclonal antibody isatuximab-irfc (Sarclisa) in combination with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT)....

Multiple Myeloma
Lymphoma

FDA Approves Ready-to-Use Version of Bortezomib for Subcutaneous Administration

The U.S. Food and Drug Administration (FDA) has approved a new presentation of bortezomib (Boruzu) for ready-to-use subcutaneous or intravenous administration. This new ready-to-use oncology product reduces the compounding preparation steps typically required with administration. Bortezomib, a...

Multiple Myeloma

Delays in Oral Antimyeloma Treatment Initiation: Role of Social Determinants of Health

A retrospective cohort study published in Blood Cancer Journal by Gasoyan et al revealed discrepancies between the timing of the initiation of any treatment and the fill of prescriptions for oral antimyeloma medications in patients with multiple myeloma, with a lower likelihood of Black and older...

Multiple Myeloma

What Is the Better Target for Bispecific Antibodies in Multiple Myeloma: BCMA or GPRC5D?

For relapsed or refractory multiple myeloma, there are three available bispecific antibodies—two that target B-cell maturation antigen (BCMA) and one that targets G protein–coupled receptor class C group 5 member D (GPRC5D). Which is the preferred target? This question was addressed at the 2024...

Multiple Myeloma
Genomics/Genetics
Issues in Oncology

Novel Insights Into Multiple Myeloma Progression

Researchers have offered a comprehensive understanding of the progression of multiple myeloma from a treatable condition to a high-risk disease by providing insights into its genetic diversity and subtypes, according to a recent study published by Skerget et al in Nature Genetics. Background...

Multiple Myeloma
Issues in Oncology

Exploring Targeted Therapies in Multiple Myeloma

Investigators have explored the multifaceted nature of multiple myeloma and the potential of targeted therapies to treat patients with the disease, as summarized in a review published by Lu et al in Molecular Biomedicine. Background Multiple myeloma is a complex hematologic malignancy with...

Multiple Myeloma

FDA Approves Daratumumab and Hyaluronidase-fihj With VRd for Multiple Myeloma

On July 30, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for induction and consolidation in patients with newly diagnosed multiple myeloma who are eligible for...

Multiple Myeloma

Two Phase III Trials Report Benefit With Isatuximab-Based Regimens in Newly Diagnosed Multiple Myeloma

In newly diagnosed, transplant-ineligible patients with multiple myeloma, treatment with the anti-CD38 monoclonal antibody isatuximab plus bortezomib, lenalidomide, and dexamethasone (VRd) led to a 40% reduction in the risk of disease progression or death and “deep and sustained responses,” almost...

Multiple Myeloma
Immunotherapy

Multiple Myeloma: Using Absolute Lymphocyte Count to Predict Outcomes After CAR T-Cell Therapy

A simple blood test that measures lymphocyte counts may predict whether patients with relapsed multiple myeloma are going to respond well to chimeric antigen receptor (CAR) T-cell immunotherapy, according to research published by Saldarriaga et al in Blood Advances. The study found that patients...

Multiple Myeloma

Relapsed or Refractory Multiple Myeloma: Activity of BCMA x CD3 Bispecific Antibody

As reported in the Journal of Clinical Oncology by Bumma et al, the phase II portion of a first-in-human phase I/II trial (LINKER-MM1) showed strong activity with the B-cell maturation antigen (BCMA) x CD3 bispecific antibody linvoseltamab in patients with relapsed or refractory multiple myeloma....

Advertisement

Advertisement

Advertisement